Parabilis Medicines(NASDAQ) PBLS

Parabilis Medicines, Inc. makes drugs to treat cancer. These medicines reach targets inside cells that others cannot hit. The company helps patients with hard-to-treat tumors.

What Parabilis Is Building

• Zolucatetide: Clinical-stage drug candidate that targets specific signaling pathways to treat solid tumors such as desmoid tumors.
• ERG Degrader: Preclinical program designed to break down specific proteins that drive the development of prostate cancer.
• ARON Degrader: Early-stage treatment targeting the androgen receptor in its active state for patients with prostate cancer.
• Helicon Platform: Discovery system that uses artificial intelligence and physics-based modeling to create stabilized helical peptides.

Recent Strategic Moves

• Entered a license and collaboration agreement with Regeneron Pharmaceuticals in May 2026 to develop antibody-helicon conjugates.
• Received a $50 million upfront payment from Regeneron in June 2026 for research and preclinical development activities.
• Completed an initial public offering in June 2026, selling 38,525,000 shares of common stock at $20.00 per share.
• Terminated a research collaboration agreement with ARTBIO in May 2026 after the partner opted out of shared research programs.

Overcoming the Undruggable Barrier

Parabilis uses its proprietary Helicon technology to reach roughly 80% of disease targets that were once thought undruggable. These molecules combine the precise targeting of large biologics with the ability of small molecules to enter cells and access internal proteins.

A Look at the Books

• Total cash, cash equivalents, and marketable securities reached $1.1 billion as of June 30, 2026.
• Net loss was $52.5 million for the three-month period ended June 30, 2026, widening 51% year over year.
• Collaboration revenue totaled $148,000 for the three-month period ended June 30, 2026.
• Research and development expenses rose to $39.4 million for the three-month period ended June 30, 2026, up 30.7% year over year.
• Net proceeds from the initial public offering and concurrent private placement totaled $787.9 million in June 2026.

Bottom Line

Parabilis has evolved from a private research entity to a well-funded public biotechnology firm with a validated discovery platform. Its specialized focus on previously inaccessible protein targets provides a unique path for developing new cancer treatments.